Pontifax

Summary

Pontifax appeared to be the VC, which was created in 2004. The main department of described VC is located in the Herzliya. The fund was located in Asia if to be more exact in Israel.

The important activity for fund was in 2017. The usual things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 7 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Pontifax performs on 4 percentage points less the average number of lead investments. The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2019.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - Israel. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight 89bio, Dynacure, Check-Cap. Among the most successful fund investment fields, there are Pharmaceutical, Health Care.

This organization was formed by Ran Nussbaum, Tomer Kariv. The overall number of key employees were 10.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Pontifax, startups are often financed by OrbiMed, Ziegler Meditech Equity Partners, Perceptive Advisors. The meaningful sponsors for the fund in investment in the same round are Docor International Management, Quark Venture, Triventures. In the next rounds fund is usually obtained by Yissum Technology Transfer Company of the Hebrew University, Docor International Management, Clal Biotechnology Industries.